OPTIMISE
Optimising access to healthcare through “no-test” tele-abortion: a randomised multicentre study in Sweden (OPTIMISE)
What is the Optimise study?
Optimise is a randomised controlled trial investigating whether an early medical abortion at home (an at-home abortion) can be provided through remote digital care, without an ultrasound scan and gynaecological examination at a clinic. We call this model of care “no-test” tele-abortion. The aim is to investigate whether “no-test” tele-abortion is as effective and safe as current at-home abortion, which is preceded by a clinic visit with an ultrasound scan and gynaecological examination. We also plan to evaluate satisfaction, contraceptive use and the cost-effectiveness of “no-test” tele-abortion. We predict that this option could help provide greater flexibility, shorter waiting times and more efficient use of healthcare resources.
Who is conducting the study and where?
Participants are recruited from abortion clinics in five regions: Jämtland-Härjedalen, Norrbotten, Västerbotten, Stockholm and Örebro. Karolinska Institutet is the research sponsor and is responsible for the study. The research has been approved by the Swedish Ethical Review Authority (ref. no. 2026-05227-01). The project is funded by the Swedish Research Council (2025-00182) and is approved by the Swedish Network for National Clinical Studies in OB/Gyn https://www.snaks.se/.
How does the study work?
A total of 978 people seeking abortion care at one of the 12 participating clinics will be recruited to the study. Participants are randomly assigned to one of two groups: The intervention group receives “no-test” tele-abortion. They receive information and instructions digitally via a website and have the abortion without a prior gynaecological examination or ultrasound scan. The control group receives current standard care, with a clinic visit including a gynaecological examination and ultrasound scan. All participants complete the abortion themselves at home using the same medicines and have access to the same telephone support and care if needed. The groups are then compared in terms of treatment effectiveness, safety, satisfaction and cost-effectiveness.
Who can take part?
Participants must be 18 years or older and healthy. They must be in early pregnancy, up to 10 weeks according to the date of their last menstrual period, and want to have a medical abortion at home. They are asked to take part when they seek abortion care at a participating clinic. An evidence-based screening tool is used during recruitment to ensure that “no-test” tele-abortion is suitable for the person seeking an abortion - for example, anyone with symptoms or risk factors for ectopic pregnancy or irregular periods cannot take part in the study.
Who is responsible for the study?
The principal investigator (PI) for the study is Associate Professor and midwife Amanda Cleeve at the Department of Women’s and Children’s Health, Karolinska Institutet. Participating researchers from Karolinska Institutet also include Kristina-Gemzell Danielsson and Margit Endler. The researchers responsible in the different regions are Malin Huber, Kerstin Haupt, Helena Carré, Ulrika Ottander, Karin Brandell, Gustaf Rejnö, and Jan Brynhildsen. Karin Brandell is a postdoctoral researcher in the project, and recruitment of a doctoral student is planned.
When is the study expected to be completed?
Recruitment begins at the end of 2026, and the study is expected to be completed in 2029.
Contact:
